Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence, clinicopathological features, and clinical outcomes of low HER2 expressed, inoperable, advanced, or recurrent gastric/gastroesophageal junction adenocarcinoma.
Nakayama I, Takahari D, Chin K, Wakatsuki T, Takamatsu M, Yamamoto N, Ogura M, Ooki A, Fukuda K, Osumi H, Fukuoka S, Shinozaki E, Yamaguchi K. Nakayama I, et al. Among authors: shinozaki e. ESMO Open. 2023 Aug;8(4):101582. doi: 10.1016/j.esmoop.2023.101582. Epub 2023 Jun 20. ESMO Open. 2023. PMID: 37348349 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 37598123
Single-organ pulmonary metastasis is a favorable prognostic factor in metastatic colorectal cancer patients treated with FOLFIRI and vascular endothelial growth factor inhibitors.
Fukuda K, Osumi H, Yoshino K, Nakayama I, Fukuoka S, Ogura M, Wakatsuki T, Ooki A, Takahari D, Chin K, Yamaguchi K, Shinozaki E. Fukuda K, et al. Among authors: shinozaki e. BMC Cancer. 2023 Jul 6;23(1):634. doi: 10.1186/s12885-023-11067-y. BMC Cancer. 2023. PMID: 37415118 Free PMC article.
A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.
Osumi H, Takashima A, Ooki A, Yoshinari Y, Wakatsuki T, Hirano H, Nakayama I, Okita N, Sawada R, Ouchi K, Fukuda K, Fukuoka S, Ogura M, Takahari D, Chin K, Shoji H, Kato K, Ishizuka N, Boku N, Yamaguchi K, Shinozaki E. Osumi H, et al. Among authors: shinozaki e. Transl Oncol. 2023 Sep;35:101718. doi: 10.1016/j.tranon.2023.101718. Epub 2023 Jun 24. Transl Oncol. 2023. PMID: 37364334 Free PMC article.
Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
Nagaoka T, Osumi H, Ueno T, Ooki A, Wakatsuki T, Nakayama I, Ogura M, Takahari D, Chin K, Matsueda K, Yamaguchi K, Shinozaki E. Nagaoka T, et al. Among authors: shinozaki e. Int J Clin Oncol. 2023 Sep;28(9):1191-1199. doi: 10.1007/s10147-023-02370-6. Epub 2023 Jun 22. Int J Clin Oncol. 2023. PMID: 37349660
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.
Nakai C, Mimaki S, Matsushima K, Shinozaki E, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shitara K, Bando H, Suzuki Y, Akagi K, Nomura S, Fujii S, Sugiyama M, Nishida N, Mizokami M, Koh Y, Koshizaka T, Okada H, Abe Y, Ohtsu A, Yoshino T, Tsuchihara K. Nakai C, et al. Among authors: shinozaki e. Int J Clin Oncol. 2023 May;28(5):654-663. doi: 10.1007/s10147-023-02318-w. Epub 2023 Mar 1. Int J Clin Oncol. 2023. PMID: 36856908 Free PMC article.
170 results